PRESSRELEASES
23 March, 2023
NEX-22 preclinical data shows controlled release of liraglutide for one month
Nanexa AB (publ) today announced positive outcome in the first preclinical study with NEX-22. In a one-month study in rats, single doses of two different PharmaShell® formulations were studied in different doses. The results show a controlled release of liraglutide, with plasma exposure over 28 days for NEX-22, compared to around 2 days for a formulation with liraglutide without the PharmaShell coating.
READ MORE16 February, 2023
Nanexa publishes year-end report for 2022
Agreement and directed issue to Novo Nordisk, solution to patent infringement lawsuit and phase 1 study with NEX-20 started
READ MORELATEST REPORTS
PRESENTATIONS
2023-02-16
Webcast med Rapportkommentar, Bokslutskommuniké 2022
2023-01-31
Aktiespararna, Aktiedagen Lund, vd David Westberg presenterar
2022-12-07
ABGSC Investor Day, VD David Westberg presenterar
MEET NANEXA
Inga planerade träffar
